Ligand Pharmaceuticals (LGND) News Today $114.64 +2.10 (+1.87%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$114.47 -0.17 (-0.15%) As of 06/18/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LGND Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Chicago Capital LLC Has $58.30 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Chicago Capital LLC grew its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 0.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 554,517 shares of the biotechnology company's stock afJune 17 at 5:56 AM | marketbeat.comWealth Enhancement Advisory Services LLC Takes $286,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Wealth Enhancement Advisory Services LLC acquired a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,66June 16 at 3:02 AM | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells $57,270.00 in StockJune 13, 2025 | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives $146.14 Consensus Target Price from AnalystsJune 13, 2025 | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Andrew Reardon Sells 500 SharesLigand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) insider Andrew Reardon sold 500 shares of the business's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $114.54, for a total value of $57,270.00. Following the completion of the transaction, the insider now directly owns 32,403 shares of the company's stock, valued at approximately $3,711,439.62. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.June 12, 2025 | marketbeat.comLGND Makes Bullish Cross Above Critical Moving AverageJune 11, 2025 | nasdaq.comLigand Announces 2025 Investor Day in New York CityJune 11, 2025 | globenewswire.comGAMMA Investing LLC Purchases 61,996 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)GAMMA Investing LLC raised its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 17,612.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,348 shares of the biotechnJune 10, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Buy" from BrokeragesLigand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) has earned an average rating of "Buy" from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 12-month price target amonJune 10, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by Congress Asset Management Co.Congress Asset Management Co. grew its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 3.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 642,712 shares of the biotechnology company's stock afterJune 7, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Andrew Reardon Sells 1,000 SharesLigand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) insider Andrew Reardon sold 1,000 shares of the stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $104.00, for a total value of $104,000.00. Following the sale, the insider now directly owns 32,903 shares in the company, valued at $3,421,912. This trade represents a 2.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.June 3, 2025 | marketbeat.comAndrew Reardon Sells 1,000 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockJune 3, 2025 | insidertrades.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $5.40 Million Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 26.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 50,401June 3, 2025 | marketbeat.comSummit Global Investments Acquires 6,407 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Summit Global Investments increased its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 145.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,825 shareJune 1, 2025 | marketbeat.comKings Path Partners LLC Reduces Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Kings Path Partners LLC decreased its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 38.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,065 shares of the biotechnology company's stockMay 31, 2025 | marketbeat.comSquarepoint Ops LLC Purchases Shares of 16,799 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Squarepoint Ops LLC purchased a new stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,799 shares of the biotechMay 31, 2025 | marketbeat.comBank of America Corp DE Purchases 2,533 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Bank of America Corp DE raised its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 2.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 107,439 shares of the biotechnology company's stock after purchasinMay 25, 2025 | marketbeat.comCastleark Management LLC Cuts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Castleark Management LLC cut its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 4.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 65,113 shares of the biotechMay 23, 2025 | marketbeat.comGraham Capital Management L.P. Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Graham Capital Management L.P. acquired a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,998 shares of the bioMay 18, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Buy" by BrokeragesShares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) have earned an average rating of "Buy" from the seven brokerages that are currently covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelMay 18, 2025 | marketbeat.comDeutsche Bank AG Purchases 15,160 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Deutsche Bank AG raised its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 5.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 289,052 shares of the biotechnology company'May 16, 2025 | marketbeat.comJanus Henderson Group PLC Acquires 5,929 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Janus Henderson Group PLC boosted its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 0.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,015,023 shares of thMay 15, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Downgraded to Sell Rating by StockNews.comStockNews.com cut Ligand Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday.May 15, 2025 | marketbeat.comLigand to Ring the Nasdaq Opening Bell on May 19, 2025May 14, 2025 | globenewswire.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Acquires $156,090.00 in StockMay 14, 2025 | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by Northern Trust CorpNorthern Trust Corp increased its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 7.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 282,957 shares of the biotechnology comMay 13, 2025 | marketbeat.comLGND: 1Q:25 ResultsMay 12, 2025 | msn.comClark Capital Management Group Inc. Increases Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Clark Capital Management Group Inc. lifted its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 44.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,277 shares of the bMay 12, 2025 | marketbeat.comDriehaus Capital Management LLC Increases Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Driehaus Capital Management LLC raised its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 70.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 162,771 shares of the biotechnology company's stock after buyingMay 11, 2025 | marketbeat.comBaird Financial Group Inc. Boosts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Baird Financial Group Inc. increased its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 8.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 77,207 shares of the biotechnMay 11, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Updates FY 2025 Earnings GuidanceLigand Pharmaceuticals (NASDAQ:LGND) updated its FY 2025 earnings guidance. The company provided EPS guidance of 6.000-6.250 for the period, compared to the consensus estimate of 6.110. The company also issued revenue guidance of $180.0 millionillion-$200.0 millionillion, compared to the consensus estimate of $191.3 millionillion.May 10, 2025 | marketbeat.comLigand Pharmaceuticals Inc (LGND) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...May 9, 2025 | finance.yahoo.comQ1 2025 Ligand Pharmaceuticals Inc Earnings Call TranscriptMay 9, 2025 | gurufocus.comLigand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comLigand Pharmaceuticals Incorporated 2025 Q1 - Results - Earnings Call PresentationMay 8, 2025 | seekingalpha.comLigand Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comMariner LLC Purchases Shares of 2,574 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Mariner LLC acquired a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,574 shares of the biotechnologyMay 8, 2025 | marketbeat.comLigand Pharmaceuticals Q1 2025 Earnings PreviewMay 7, 2025 | seekingalpha.comDimensional Fund Advisors LP Buys 16,003 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Dimensional Fund Advisors LP lifted its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 2.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 723,019 shares of the biotechnology company's stockMay 3, 2025 | marketbeat.comLigand Pharmaceuticals (LGND) Projected to Post Earnings on ThursdayLigand Pharmaceuticals (NASDAQ:LGND) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-ligand-pharmaceuticals-incorporated-stock/)May 3, 2025 | marketbeat.comRaymond James Financial Inc. Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Raymond James Financial Inc. bought a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 21,830 shares of the biotechnology company's stock, valued at approximatMay 2, 2025 | marketbeat.comLigand to Participate in May Investor ConferencesMay 1, 2025 | globenewswire.comIs Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Trading At A 49% Discount?April 30, 2025 | finance.yahoo.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Acquired by Wells Fargo & Company MNWells Fargo & Company MN boosted its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 29.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,220 shaApril 30, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Sold by Barclays PLCBarclays PLC cut its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 8.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,972 shares of the bApril 29, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Position Boosted by Penn Capital Management Company LLCPenn Capital Management Company LLC lifted its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 4.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 104,430 shares of the bApril 26, 2025 | marketbeat.comXTX Topco Ltd Takes Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)XTX Topco Ltd purchased a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,067 shares of the biApril 26, 2025 | marketbeat.comLigand to Report First Quarter 2025 Financial Results on May 8, 2025April 24, 2025 | globenewswire.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Acquired by Uniplan Investment Counsel Inc.Uniplan Investment Counsel Inc. increased its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 28.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 68,155 shares of the biotechApril 24, 2025 | marketbeat.comLGND: Pelthos To Become Public CompanyApril 23, 2025 | msn.com Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Email Address LGND Media Mentions By Week LGND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LGND News Sentiment▼0.820.64▲Average Medical News Sentiment LGND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LGND Articles This Week▼65▲LGND Articles Average Week Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RGEN News Today HALO News Today MDGL News Today IONS News Today ALKS News Today BCRX News Today FOLD News Today INVA News Today CLDX News Today DVAX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LGND) was last updated on 6/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LGND Stock Free LGND Stock Alerts